GlassScriptPhysician profile
Katherine G Roth
NPI 1083695233
$33,954.84
in general payments reported to CMS, 2019-2025
67 companies · $5,903 in 2025
The $5,903 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,291 · 2020: $4,067 · 2021: $4,785 · 2022: $5,060 · 2023: $5,306 · 2024: $4,543 · 2025: $5,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,751.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,616.48 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Abbvie INC. | $3,514.44 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Teva Pharmaceuticals USA, INC. | $2,249.95 | 2019-2024 | Austedo Xr, Austedo |
| Lundbeck LLC | $2,174.92 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $2,115.81 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $1,874.88 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Amgen INC. | $1,694.65 | 2019-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $1,498.42 | 2019-2025 | Crexont, Rytary, Ongentys |
| Pfizer INC. | $1,256.83 | 2021-2025 | |
| Argenx US, INC. | $1,150.29 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $1,064.99 | 2020-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $876.35 | 2019-2025 | |
| Sk Life Science, INC. | $830.68 | 2020-2024 | |
| Genzyme Corporation | $812.55 | 2019-2022 | |
| Emd Serono, INC. | $743.64 | 2019-2024 | Mavenclad, Mavenclad |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.